← Leaderboards
Chinthalapally V. Rao
Oklahoma City Va Medical Center
$10,896,885
Attributed
$10,896,885
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,896,885 · 8
VA$0 · 3
By mechanism
R01$7,825,231 · 4
N01$2,463,904 · 3
UG3$607,750 · 1
I01$0 · 2
IS1$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Dose”
- Lawrence Corey · Fred Hutchinson Cancer Center$251,944,397
- Sharon A Nachman · Johns Hopkins University$213,337,729
- David Heimbrook · Leidos Biomedical Research, Inc.$146,807,554
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$134,297,561
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$124,321,134
- Peter C Adamson · National Childhood Cancer Foundation$122,197,823
Research focus
DoseTumorMalignant NeoplasmsIn VivoTissuesMaleChemopreventive AgentResponseColorectal CancerBaseHigh RiskPreventCell ProliferationCancer PreventionTumor GrowthPreventionPropertyRattusColorectal Cancer PreventionModificationNeoplastic CellColonic NeoplasmsApoptosisColon Carcinoma
Grant awards (43)
Discovery and Development of Natural Products for Interception of CRC$303,875
UG3 · FY2025 · CA · contact PI
Targeting GCNT3 for Pancreatic Cancer$0
I01 · FY2025 · VA · contact PI
TO TITLE: A NOVEL MRNA VACCINE TO PREVENT TRIPLE NEGATIVE BREAST CANCERIDIQ TITLE: PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS$764,880
N01 · FY2024 · CA · contact PI
Discovery and Development of Natural Products for Interception of CRC$303,875
UG3 · FY2024 · CA · contact PI
Contract Orientation and Kickoff Meeting$3,500
N01 · FY2024 · CA · contact PI
Targeting GCNT3 for Pancreatic Cancer$0
I01 · FY2024 · VA · contact PI
Targeting GCNT3 for Pancreatic Cancer$0
I01 · FY2023 · VA · contact PI
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.$244,086
N01 · FY2022 · CA · contact PI
Targeting GCNT3 for Pancreatic Cancer$0
I01 · FY2022 · VA · contact PI
Safer Approaches to CRC Chemoprevention$389,770
R01 · FY2021 · CA · contact PI
Safer Approaches to CRC Chemoprevention$217,481
R01 · FY2021 · CA · contact PI
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS. TASK ORDER TITLE: URINARY BLADDER CANCER PREVENTIO$785,160
N01 · FY2020 · CA · contact PI
EVALUATION OF TWO DIFFERENT CLASSES OF COMPOUNDS (STAT3 INHIBITORS AND SERMS) FOR THE PREVENTION OF URINARY BLADDER CANCER.$666,278
N01 · FY2020 · CA · contact PI
Safer Approaches to CRC Chemoprevention$424,881
R01 · FY2020 · CA · contact PI
Targeting mPGES-1/5-LOX for Prevention of CRC in High-Risk Veterans$0
I01 · FY2020 · VA · contact PI
Safer Approaches to CRC Chemoprevention$435,594
R01 · FY2019 · CA · contact PI
ShEEP Request for CTL ImmunoSpot S6 Universal Analyzer$0
IS1 · FY2019 · VA · contact PI
Targeting mPGES-1/5-LOX for Prevention of CRC in High-Risk Veterans$0
I01 · FY2019 · VA · contact PI
Safer Approaches to CRC Chemoprevention$446,611
R01 · FY2018 · CA · contact PI
Targeting mPGES-1/5-LOX for Prevention of CRC in High-Risk Veterans$0
I01 · FY2018 · VA · contact PI
Safer Approaches to CRC Chemoprevention$458,611
R01 · FY2017 · CA · contact PI
Targeting mPGES-1/5-LOX for Prevention of CRC in High-Risk Veterans$0
I01 · FY2016 · VA · contact PI
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer$280,471
R01 · FY2014 · CA · contact PI
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer$271,796
R01 · FY2013 · CA · contact PI
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer$289,145
R01 · FY2012 · CA · contact PI
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer$289,145
R01 · FY2011 · CA · contact PI
HMG-CoA Reductase and Polyamine Inhibitors for Prevention of Colorectal Cancer$298,087
R01 · FY2010 · CA · contact PI
PREVENTION OF COLORECTAL CANCER BY iNOS AND COX-2 SELECTIVE INHIBITORS$284,764
R01 · FY2008 · CA · contact PI
PREVENTION OF COLORECTAL CANCER BY iNOS AND COX-2 SELECTIVE INHIBITORS$284,764
R01 · FY2007 · CA · contact PI
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS$293,268
R01 · FY2006 · CA · contact PI
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER$286,472
R01 · FY2006 · CA · contact PI
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER$325,963
R01 · FY2005 · CA
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS$300,325
R01 · FY2005 · CA
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER$358,225
R01 · FY2004 · CA
PREVENTION OF CRC BY iNOS AND COX-2 SELECTIVE INHIBITORS$300,325
R01 · FY2004 · CA
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER$263,700
R01 · FY2004 · CA
MECHANISMS FOR CHEMOPREVENTION OF COLON CANCER$32,230
R01 · FY2004 · CA
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER$358,225
R01 · FY2003 · CA
HMG CoA REDUCTASE AND COX2 INHIBITORS IN COLON CANCER$356,556
R01 · FY2002 · CA
MECHANISMS FOR CHEMOPREVENTION OF COLON CANCER$171,403
R01 · FY2002 · CA
MECHANISMS FOR CHEMOPREVENTION OF COLON CANCER$202,715
R01 · FY2001 · CA
MECHANISMS FOR CHEMOPREVENTION OF COLON CANCER$204,704
R01 · FY2000 · CA
EFFICACY STUDIES OF CHEMOPREVENTIVE AGENTS IN ANIMAL MOD$0
N01 · FY2000 · CN